Trial reportCurrent oncology (Toronto, Ont.)2020
Efficacy of
Trial report in Current oncology (Toronto, Ont.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Theranostic Radiopharmaceuticals of Somatostatin Receptors for Patients with Neuroendocrine Tumors: Agonists Versus Antagonists-A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Survival predictors ofJournal of cancer research and clinical oncology · 2022Trial
- Pancreatic Neuroendocrine Tumors: From Benchside to Surgical Treatment.Medicina (Kaunas, Lithuania) · 2026Review
- Safety and efficacy of re-treatment with [European journal of nuclear medicine and molecular imaging · 2025Article
- Analysis of clinical factors associated with incomplete standard protocolJapanese journal of radiology · 2025Article
- Eastern Canadian Gastrointestinal Cancer Consensus Conference 2024.Current oncology (Toronto, Ont.) · 2025Article
- Treatment Patterns of Pancreatic Neuroendocrine Tumor (pNET) Patients at Two Canadian Cancer Centres.Current oncology (Toronto, Ont.) · 2025Article
- Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update.Current oncology reports · 2024Review
- Establishing a robust radioligand therapy program: A practical approach for North American centers.Cancer medicine · 2024Review
- Article
- Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Review
- Review
- Understanding the Radiobiological Mechanisms Induced byInternational journal of molecular sciences · 2022Article
- Review
- The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?Frontiers in endocrinology · 2022Review
- Toxicity and Tolerability ofCurrent radiopharmaceuticals · 2022Article
- Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated WithFrontiers in endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptide receptor radionuclide therapy (PRRT) has been recently established as a treatment option for progressive gastro-entero-pancreatic neuroendocrine tumors (NETs) including four 200 mCi induction cycles. The purpose of this phase 2 trial is to expand use of PRRT to different types of NETs with the application of dose adjustment and evaluate value of maintenance therapy in patients who had disease control on induction therapy. Forty-seven PRRT naïve NET patients with different primary origin received
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.